Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension.
about
Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT)The effect on intraocular pressure of latanoprost once or four times dailyA double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension.Effects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and ocular hypertension.Mechanism related to reduction of intraocular pressure by melanocortins in rabbits.Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol.A review of the use of latanoprost for glaucoma since its launch.Latanoprost--a promising new glaucoma drug.Activation of FP prostanoid receptor isoforms leads to Rho-mediated changes in cell morphology and in the cell cytoskeleton.Effect of topical ophthalmic latanoprost 0.005% solution alone and in combination with diclofenac 0.1% solution in healthy horses: a pilot study.A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension.
P2860
Q24319949-B40B18B8-FECA-4ACD-8388-F1C0EA422F0FQ28360261-CF3BCB7C-183F-404E-8FA3-DDF6B0D8EA50Q35298399-BD60A48F-6E4B-488B-B1DA-A1BEF050A61CQ35300174-03D55318-5A57-437C-BA1E-2694A0604BB1Q35312946-5CE17A04-9860-42D5-B70D-772CC5441264Q37250462-57A2C689-0A1B-4B6F-9D99-46D1AFC433BFQ37309885-3B12A0E7-0F0A-4DE7-B300-B58F18A0EA77Q37986149-BB985ACD-C901-4845-AB41-E096EC83048BQ39706170-B437325A-35AB-41EC-A1CA-AF29653D8EF6Q40914056-42472D8E-0F66-4049-81D3-EFE18ABE526CQ53559582-67E043CC-5CF4-4E35-ACE0-4DD48D342CA1Q53989474-80BE1193-95A1-46FA-B67B-473213AC5CE2
P2860
Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Intraocular pressure reduction ...... ents with ocular hypertension.
@en
Intraocular pressure reduction ...... ents with ocular hypertension.
@nl
type
label
Intraocular pressure reduction ...... ents with ocular hypertension.
@en
Intraocular pressure reduction ...... ents with ocular hypertension.
@nl
prefLabel
Intraocular pressure reduction ...... ents with ocular hypertension.
@en
Intraocular pressure reduction ...... ents with ocular hypertension.
@nl
P2093
P1433
P1476
Intraocular pressure reduction ...... ents with ocular hypertension.
@en
P2093
C B Camras
J S Lustgarten
J Stjernschantz
R A Schumer
P304
P356
10.1001/ARCHOPHT.1992.01080240073034
P407
P577
1992-12-01T00:00:00Z